Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 9/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13162036 | 0.89 | NAMPT (0.50) | SIRT3TDP1HTR3ATGFBR1SMYD3 | |
| SCHEMBL13162009 | 0.89 | NAMPT (0.50) | SIRT3TDP1HTR3ATGFBR1SMYD3 | |
| SCHEMBL13162007 | 0.86 | SIRT3 (0.53) | SIRT3TDP1SMYD3NPC1RAB9A | |
| SCHEMBL13161975 | 0.86 | SMN1; SMN2 (0.49) | SIRT3TDP1TGFBR1SMYD3NPC1 | |
| SCHEMBL13162024 | 0.84 | RAB9A (0.57) | SIRT3TDP1SMYD3NPC1RAB9A | |
| SCHEMBL19701355 | 0.80 | SMYD3 (0.56) | SIRT3TDP1SMYD3NPC1RAB9A | |
| SCHEMBL21489690 | 0.80 | SMYD3 (0.56) | SIRT3TDP1SMYD3NPC1RAB9A | |
| SCHEMBL7461632 | 0.79 | KDM4E (0.50) | TDP1HTR3ATGFBR1SMYD3PDE10A | |
| SCHEMBL13162654 | 0.78 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30804749 | 0.76 | HSD17B10 (0.62) | TDP1NPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | SIRT3 420/4885TDP1 2603/4885HTR3A 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.